Q1 2022 Results

Company overview Financial review 2022 priorities Appendix References Expected currency impact for full year 2022 Currency impact vs. PY %pts, assuming late-April exchange rates prevail in 2022 2 FX impact on Net sales FY 2021 I FX impact on Core operating income I 2 T -4 -4 I -5 to -6 I -6 -6 -5 I Q1 Q2 FY FY Q1 Q2 FY I I 2022 2021 2022 Actual Simulation 25 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation